Vulvovaginal Candidiasis Treatment Market to be Dominated by Clotrimazole Drug Class Type through 2028
Increasing prevalence of chronic diseases is expected
to drive the growth of global vulvovaginal candidiasis treatment in the
forecast period, 2024-2028.
According to TechSci Research report, “Vulvovaginal Candidiasis
Treatment Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028F”, the
global dental contouring market is anticipated to grow at an impressive rate in
the forecast period, 2024-2028. This can be ascribed to the increasing prevalence
of diabetes cases and increasing unrestrained usage of antibiotics leading to
high prevalence of yeast infection among individuals across the globe.
Additionally, increasing demand for better treatment and the rising burden of
different chronic diseases like neurological disorder, and cancer, especially
in the developed countries in the North America and Europe, are expected to
create lucrative opportunities for market growth in the coming years. Besides, increasing
research and development activities in healthcare industry is further expected
to support the market growth. Similarly, growing approval of newly developed
antifungal drugs and increasing the number of market players are expected to
boost market growth during the forecast period. Also, growing awareness about
new drugs for the treatment of fungal diseases and growing demand for advanced
therapeutic options will drive the market growth over the years.
However, increasing
resistance for antifungal drugs among the population is slowing down the growth
of global vulvovaginal candidiasis treatment market in the forecast period.
Similarly, high risks and complications associated with drugs such as the
incidence of miscarriage due to fluconazole and treatments may hamper the vulvovaginal
candidiasis treatment market growth during the forecast period. Also, the lack
of awareness about maintaining good hygiene among the female population, in
emerging countries, can further restrict the growth of the global vulvovaginal
candidiasis treatment market.
Browse over XX market data
Figures spread through XX
Pages and an in-depth TOC on "Global Vulvovaginal Candidiasis Treatment Market"
The global vulvovaginal
candidiasis treatment market
can be segmented by drug class, by route of administration, by distribution
channel and by region.
Based on drug class, the global vulvovaginal
candidiasis treatment market can be segmented into Clotrimazole,
Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others. The clotrimazole segment dominated the market
in 2022 and is expected to continue maintaining its dominance throughout the
forecast period. This can be ascribed to high efficiency and increasing usage
of clotrimazole drug for the treatment of acute vulvovaginal candidiasis
disease.
Based on route of administration, the market
can be segmented into Oral, Intravenous, Topical. The oral segment is expected to dominate during
the forecast period on account of the fact that most of the acute vulvovaginal
candidiasis treatment drugs are taken orally and increasing the large patient
pools in the hospitals. Similarly, the increasing demand for prescription
products because of growing moderate to severe disease cases will further
propel the market growth over the years.
Major companies operating in global vulvovaginal candidiasis treatment market
are:
- Astellas Pharma Inc.
- Mycovia Pharmaceuticals, Inc.
- Basilea Pharmaceutica Ltd.
- Scynexis, Inc.
- Grupo Ferrer Internacional, S.A.
- Pfizer, Inc.
- Pacgen Life Science Corporation
- NovaDigm Therapeutics, Inc.
- Cidara Therapeutics, Inc.
- Amplyx Pharmaceuticals Inc.
For instance, on August 26, 2020, Mycovia
Pharmaceuticals, Inc. published positive results for the Phase II clinical
trials, which was conducted for testing the safety and efficacy of their oral
drug candidate oteseconazole (VT-1161), an antifungal drug, for the treatment
of vulvovaginal candidiasis.
For instance, on April 29, 2020, researchers
at the University of Bristol, U.K. found that C12AHL, a chemical released from
the bacterial species Pseudomonas aeruginosa, acts as the chemical signal for
Candida species.
Download Free Sample Report
Customers can also request for 10% free customization on this report.
“North
America is expected to dominate in the global vulvovaginal candidiasis
treatment market due to the developed reimbursement procedures for the
diagnosis and testing of vaginal fungal infection. Similarly, increasing the
number of hospital-acquired infections is expected to propel the growth of the
market over the years. Furthermore, the increasing prevalence of vaginal fungal
infections among the population and major key players investing in the research
and development sector for developing new drugs for the treatment is further
contributing to the demand for vulvovaginal candidiasis treatment. Also, the
presence of other tropical products the counter and prescription formulations
will drive the market growth during the forecasted period. Besides, the availability
of skilled professionals and early adoption of advanced treatments for the treatment
of different vulvovaginal candidiasis infections in the region, are further
expected to create lucrative opportunities for the market growth” said Mr.
Karan Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“Vulvovaginal Candidiasis Treatment Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Drug Class (Clotrimazole, Nystatin, Fluconazole,
Ketoconazole, Terbinafine, Terconazole, Others), By Route of Administration
(Oral, Intravenous, Topical), By Distribution Channel (Hospital Pharmacy,
Retail Pharmacy, Online Pharmacy), By Region and Competition”, has evaluated the future growth potential of global vulvovaginal
candidiasis treatment market and provides statistics & information on
market size, structure, and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in global vulvovaginal
candidiasis treatment market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com